ONO Pharmaceutical Co Ltd (OPHLF)
OTHER OTC:OPHLF
Holding OPHLF?
Track your performance easily

ONO Pharmaceutical Co (OPHLF) Stock Price & Analysis

15 Followers

OPHLF Stock Chart & Stats


ONO Pharmaceutical Co News

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%4.45%8.46%87.09%
0.00%
Insiders
8.46% Other Institutional Investors
87.09% Public Companies and
Individual Investors

OPHLF FAQ

What was ONO Pharmaceutical Co Ltd’s price range in the past 12 months?
ONO Pharmaceutical Co Ltd lowest stock price was $12.59 and its highest was $19.84 in the past 12 months.
    What is ONO Pharmaceutical Co Ltd’s market cap?
    Currently, no data Available
    When is ONO Pharmaceutical Co Ltd’s upcoming earnings report date?
    ONO Pharmaceutical Co Ltd’s upcoming earnings report date is Oct 31, 2024 which is in 40 days.
      How were ONO Pharmaceutical Co Ltd’s earnings last quarter?
      ONO Pharmaceutical Co Ltd released its earnings results on Jul 31, 2024. The company reported $0.368 earnings per share for the quarter, missing the consensus estimate of $0.383 by -$0.015.
        Is ONO Pharmaceutical Co Ltd overvalued?
        According to Wall Street analysts ONO Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does ONO Pharmaceutical Co Ltd pay dividends?
          ONO Pharmaceutical Co Ltd pays a Annually dividend of $0.28 which represents an annual dividend yield of 3.94%. See more information on ONO Pharmaceutical Co Ltd dividends here
            What is ONO Pharmaceutical Co Ltd’s EPS estimate?
            ONO Pharmaceutical Co Ltd’s EPS estimate is $0.37.
              How many shares outstanding does ONO Pharmaceutical Co Ltd have?
              ONO Pharmaceutical Co Ltd has 498,692,800 shares outstanding.
                What happened to ONO Pharmaceutical Co Ltd’s price movement after its last earnings report?
                ONO Pharmaceutical Co Ltd reported an EPS of $0.368 in its last earnings report, missing expectations of $0.383. Following the earnings report the stock price went down -1.253%.
                  Which hedge fund is a major shareholder of ONO Pharmaceutical Co Ltd?
                  Currently, no hedge funds are holding shares in OPHLF
                  ---

                  ONO Pharmaceutical Co Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  ONO Pharmaceutical Co Ltd

                  Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
                  ---

                  OPHLF Stock 12 Month Forecast

                  Average Price Target

                  $14.60
                  ▲(0.07% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","19":"$19","13.75":"$13.75","15.5":"$15.5","17.25":"$17.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.992774,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.211422,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,13.75,15.5,17.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Sep<br/>2024","25":"Sep<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.24,14.374828769230769,14.50965753846154,14.644486307692308,14.779315076923078,14.914143846153847,15.048972615384615,15.183801384615386,15.318630153846154,15.453458923076923,15.588287692307693,15.723116461538462,15.857945230769232,{"y":15.992774,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.24,14.267692307692307,14.295384615384615,14.323076923076924,14.350769230769231,14.378461538461538,14.406153846153845,14.433846153846154,14.461538461538462,14.489230769230769,14.516923076923076,14.544615384615385,14.572307692307692,{"y":14.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.24,14.160878615384616,14.081757230769231,14.002635846153847,13.923514461538462,13.844393076923078,13.765271692307692,13.686150307692309,13.607028923076923,13.52790753846154,13.448786153846154,13.36966476923077,13.290543384615386,{"y":13.211422,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.8,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.98,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.34,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.58,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.26,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.55,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.28,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.76,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.47,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.76,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.49,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1725580800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Takeda Pharmaceutical Company
                  Jazz Pharmaceuticals
                  Novartis
                  GlaxoSmithKline

                  Best Analysts Covering OPHLF

                  1 Year
                  1 Year Success Rate
                  1/1 ratings generated profit
                  100%
                  1 Year Average Return
                  +2.00%
                  downgraded a sell rating 22 days ago
                  Copying Fumiyoshi Sakai's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +2.00% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis